SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid speculation about its potential role in powering AI data centers, driving a surge in the stock price. While some celebrate technical breakouts and upside potential, others caution about bubble risks given the company's pre-revenue status and high valuation. Community chatter revolves around whether the hype is justified or if a correction is imminent.

AGM Group Holdings, Inc. is a technology company, which engages in the provision of financial solutions. It focuses on the research and development of blockchain-oriented ASIC chip, production of encryption mining machines, and financial technology software services. Its products and services include technology hardware research and development, and assembling and sales of technology hardware. The company was founded by Zhen Tao Jiang and Wen Jie Tang on April 27, 2015 and is headquartered in Hong Kong.

AGM Group Holdings Inc - Ordinary Shares - Class A

AGMH is trending as traders discuss its recent surge, potentially driven by news regarding the purchase of BTC miners. Community members are pointing to its low float and high short interest as contributing factors, while others suggest it could be part of a broader Hong Kong-related stock trend. Some traders are also comparing it to other high-flying stocks, while cautioning about potential volatility.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

FNMA is trending as the community speculates about an upcoming IPO, driven by comments from insiders and analysts suggesting a potential public offering soon; excitement is further fueled by positive price target updates. Community members are actively discussing strategies around holding shares through the IPO, the potential for significant gains, and the possibility of government actions affecting shareholder value. Chatter revolves around the balance between short-term volatility on the OTC market and long-term potential upon relisting on a major exchange.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as part of a broader surge in quantum computing stocks, possibly fueled by news of a recent Air Force contract and progress in DARPA's Quantum Benchmarking Initiative. The community is actively debating whether the stock is overvalued and ripe for profit-taking or if it has more room to run, with some speculating about potential mergers or acquisitions in the sector. Talk of short squeezes, government contracts, and fidelity milestones has also been circulating among investors.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as discussions revolve around its potential participation in a White House-backed eVTOL pilot program and the implications of a military pivot with Anduril, with some seeing it as undervalued compared to peers like Joby. The community is closely watching for news catalysts, FAA progress, and key price levels that could trigger a short squeeze, while also debating the stock's long-term potential.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending as part of a broader conversation around quantum computing stocks, with community members discussing its potential for a range break. Some traders believe NXXT is accumulating shares on dips, while others express skepticism about the sector's current valuations and commercial viability. Bullish investors cite news catalysts expected before year-end and the potential for a short squeeze, while bears point to the company's minimal revenue.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending amid discussions about its valuation, growth potential, and analyst price targets, with some community members expressing bullish sentiment and anticipating a rebound. The stock's movement is also being attributed to broader market factors and potential impacts from coffee tariffs, sparking debate among investors. Some are viewing the current price as a buying opportunity, while others remain cautious.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as the CDC advisory panel reviews COVID-19 vaccine recommendations and discusses potential safety concerns with mRNA vaccines, leading some to speculate about a possible advantage for NVAX as a non-mRNA alternative. The community is actively debating the implications of the meeting and expressing frustration over the lack of media coverage differentiating Novavax from mRNA vaccines. Some investors hope that Novavax will be positioned as a safer option amid scrutiny of mRNA technology, while others remain skeptical about the company's ability to capitalize on the situation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors discuss its potential to reach $100 amidst bullish sentiment and comparisons to other high-growth tech stocks. Community members are highlighting the company's involvement in AI infrastructure and data centers, with some speculating about potential news or announcements soon. There's also broader discussion around partnerships and contracts that could drive further growth.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending as investors discuss its potential amid growing interest in quantum computing and AI, with some drawing comparisons to NVDA's early days. Community members are excited about the stock's recent surge, potential partnerships, and takeover bids, while others are wary of the high valuation and insider selling. The broader context involves government initiatives and potential gamma squeezes driving interest in the quantum computing sector as a whole.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Artificial intelligence (AI)-powered decision intelligence solutions company Big Bear.ai Holdings, Inc.’s (BBAI) trended on Stocktwits early Tuesday. The stock also gathered some momentum in the overnight trading, over 3% in the overnight session.&nbsp;The 24-hour message volume on the Bigbear stream on Stocktwits was up over 500%. Retail sentiment toward<a href="https://stocktwits.com/symbol/BBAI"> Bigbear stock</a> improved to ‘extremely bullish’ by early Tuesday from ‘bullish’ a day ago.<figure class="image"><img style="aspect-ratio:616/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_2_26_23_AM_png_1d434e28ff.webp" alt="Screenshot 2025-09-16 at 2.26.23 AM.png" width="616" height="54"><figcaption>BBAI sentiment and message volume as of 2:25 a.m. ET, Sept. 16 | source: Stocktwits</figcaption></figure>The chatter on the platform centered around a recent&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2025/20030932.pdf">disclosure</a> by Rep. Lisa McClain (R-Mich.) regarding the purchase of Bigbear stock worth between $15,000 and $50,000 as part of a 401K account held with Charles Schwab.&nbsp;The trade was done on Aug. 7, with the disclosure coming along with a series of other transactions filed by the representative on Friday. An X handle, going by the name Nancy Pelosi Stock Tracker, said this was the first time a politician had bought Bigbear shares, and that the company earned the majority of its revenue from government contractors.In mid-August, when Bigbear released its second-quarter results, it lowered its full-year guidance due to disruptions in federal contracts from efficiency efforts, most notably in programs that support the U.S. Army, as it seeks to consolidate and modernize its data architecture.Incidentally, McClain’s purchase was made a few days before the earnings report was published.Kevin McAleenan, Bigbear’s CEO since January, has previously worked with U.S. national security agencies, including the U.S. Department of Homeland Security (DHS) during the first Trump administration. He has also served as the Commissioner of U.S. Customs and Border Protection.A bullish watcher said $4.75 is the bottom line for Bigbear stock but looked ahead to a “bullish ride.” The stock settled the previous session at $5.09.<stembedurl>https://stocktwits.com/Yousefasfour/message/628785491</stembedurl>Another user referred to the Congresswoman’s stock purchase and wondered whether that was sort of an indication that the company might land more government contracts.<stembedurl>https://stocktwits.com/mentally1sick/message/628785405</stembedurl>Bigbear stock has gained more than 14% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/tim-cook-says-apple-s-600-b-us-investment-extraordinary-commitment/chwy42rRdyI">Tim Cook Calls Apple’s $600B US Investment An ‘Extraordinary Commitment’ With Potential ‘Domino Effect’</a>

In this photo illustration, a person holds a smartphone displaying the logo of BigBear.ai Holdings, Inc. (NYSE: BBAI), on August 8, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Bigbear Stock Sparks Retail-Trader Buzz As Congressional Disclosure Fuels Speculation Of Federal Wins

The trade was done on Aug. 7, with the disclosure coming along with a series of other transactions filed by the representative on Friday.

Equity

Cadrenal Therapeutics, Inc. (CVKD) on Monday announced the acquisition of new assets from eXIthera Pharmaceuticals.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/15/3149938/0/en/Cadrenal-Therapeutics-Enhances-Anticoagulation-Pipeline-Through-Acquisition-of-eXIthera-s-Portfolio-of-Factor-XIa-Inhibitors.html">said</a> that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings. As per the deal, eXIthera will receive milestone payments from Cadrenal totaling up to $15 million, subject to the realization of certain future clinical and regulatory milestones. eXIthera will also be entitled to royalties on global sales of the acquired assets upon future commercialization.CVKD shares jumped 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The deal includes eXIthera’s portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, a new class of anticoagulants. This includes eXIthera’s lead asset, Frunexian, being studied for acute anticoagulation, EP-7327, an oral small molecule candidate for chronic indications, and an extensive portfolio of additional small molecules.“With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Cadrenal CEO Quang X. Pham.“With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk,” he added.Sichuan Haisco Pharmaceuticals retains rights to Frunexian in China under a pre-existing license agreement, the company said. Cadrenal will, however, be entitled to receive royalties of Frunexian sales in China.CVKD stock is down 8% this year but up approximately 20% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-rate-cut-this-week-too-late-powell-bigger-than-he-had-in-mind/chwwONNRdUh">Trump Says ‘Too Late’ Powell Must Cut Rates Now, And ‘Bigger Than He Had In Mind’ Ahead Of Fed Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.

Shares of&nbsp;micro-cap Quantum Corp. (QMCO) declined sharply in the after-hours session on Wednesday following its disappointing quarterly results.<a href="https://stocktwits.com/symbol/QMCO">Quantum stock</a> ended the after-hours session down 15.40% but has since then trimmed some of the losses in overnight trading.Retail users of Stocktwits have shrugged off the stock drop and remained ‘extremely bullish’ (92/100) as of late Wednesday, and the message volume improved to ‘extremely high.’ The 24-hour message volume change leading up to late Wednesday was over 500%.<figure class="image"><img style="aspect-ratio:618/49;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_10_at_10_12_07_PM_png_6bb215f787.webp" alt="Screenshot 2025-09-10 at 10.12.07 PM.png" width="618" height="49"><figcaption>QMCO sentiment and message volume as of 10:10 p.m. ET, Sept. 10 | source: Stocktwits</figcaption></figure>Quantum, a data management platform company, reported an adjusted loss per share of $1.58 for the first quarter of fiscal year 2026, slightly narrower than the $1.59 loss reported for the year-ago quarter.Revenue fell to $64.3 million from $72.3 million reported for the year-ago quarter. Analysts, on average, expected a loss per share of $0.43 and revenue of $70.7 million for the quarter, according to Fiscal.ai.The adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) widened to a negative $6.5 million from a negative $2.2 million last year. The company’s cash position improved to $37.5 million at the end of the quarter from $16.6 million at the end of the March quarter.Looking forward, Quantum guided to second-quarter revenue of $61 million, plus or minus $2 million, below the analysts’ consensus of $72.35 million. The company’s adjusted loss per share guidance is $0.26, plus or minus $0.10, compared to the analysts' $0.40 loss per share estimate. It aims to achieve breakeven EBITDA for the quarter.Hugues Meyrath, who assumed the CEO role at the company in June, said, “Leveraging extensive industry experience and my familiarity of the Company as a board member, the Company has implemented immediate and ongoing actions aimed at further improving the cost structure and balance sheet.”“Despite the disappointing performance in [the] fiscal first quarter, we are encouraged by positive developments and renewed business prospects following the refresh of our leadership team. We expect our decisive actions to result in noticeably improved bottom-line performance beginning in the September quarter.”Quantum stock is down about 85% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/toyota-reshapes-us-operations-under-tariff-pressure-ev-su-vs-coming-to-kentucky-lexus-es-shifts-to-japan/chwNbuKRdHb">Toyota Reshapes US Operations Under Tariff Pressure — EV SUVs Coming To Kentucky, Lexus ES Shifts To Japan</a>

In this photo illustration, the logo of Quantum Corporation is displayed on a smartphone screen with a blurred version of the company's branding in the background on June 27, 2025 in Chongqing, China. 

Why Quantum Corp. Stock Plunged In Today’s After-Hours

CEO Hugues Meyrath said the company’s decisive actions would result in noticeably improved bottom-line performance beginning in the September quarter.

H.C. Wainwright on Monday set a price target of $11 for CervoMed (CRVO) shares while keeping a ‘Neutral’ rating. The target implies a premium of nearly 5% from the stock’s closing price on Friday.The regulatory outlook for Neflamapimod should be clarified in the near term, the analyst told investors in a research note. The firm noted CervoMed is actively preparing for discussions with the U.S. Food and Drug Administration (FDA), which management expects to take place during the fourth quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRVO">CervoMed</a> trended in the ‘extremely bullish’ territory, while message volume is at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_12_48_27_PM_png_0e348d0430.webp" alt="CRVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>CRVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>Late in July, Cervomed <a href="https://stocktwits.com/news-articles/markets/equity/cervomed-dementia-drug-slows-disease-progression-in-study/choeuj6R5xa">said</a> that Neflamapimod continued to slow disease progression in a type of dementia during the extension phase of its mid-stage trial. Dementia with Lewy Bodies (DLB) patients treated with Neflamapimod showed a 54% risk reduction in clinically significant worsening at week 32 of treatment, the company said.DLB is a type of dementia characterized by the presence of Lewy bodies, which are protein clumps, in the brain. It is the second most common form of neurodegenerative dementia, following Alzheimer's disease.The company then also confirmed that it is looking forward to initiating late-stage trials and is preparing to meet with the U.S. Food and Drug Administration in the fourth quarter to align on the trial design.In the second quarter of 2025, CervoMed also enrolled the first patients in a mid-stage trial of Neflamapimod in patients recovering from acute stroke. It also initiated a mid-stage trial of Neflamapimod in patients with the nonfluent/agrammatic variant of primary progressive aphasia (PPA) – a subtype of frontotemporal dementia (FTD).Neflamapimod was granted Orphan Drug designation for the treatment of FTD in November 2024. Frontotemporal dementia (FTD) is a group of brain disorders characterized by the progressive degeneration of the brain's frontal and temporal lobes, leading to changes in personality, behavior, and language.According to data from Koyfin, all six analysts covering CervoMed rate it a ‘Buy’. The stock has an average price target of $21.50.CRVO stock is up 334% this year but down approximately 36% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-stock-slips-after-us-regulator-probes-287000-chrysler-minivans/chwhGZoRdrX">Stellantis Stock Slips After US Regulator Probes 287,000 Chrysler Minivans Over Concerns Regarding Electric Power Steer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon

H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon 

H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.


Nukkleus Inc. (NUKK) and Mandragola on Friday announced the establishment of a strategic joint venture focused on commercial and defense-oriented infrastructure modernization.Mandragola is an Israeli business development and investment company specializing in advanced technologies and strategic partnerships. The companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/29/3141492/0/en/Nukkleus-Inc-Expands-Aerospace-Defense-Footprint-with-Strategic-European-Joint-Venture.html">said</a> that they intend to establish advanced manufacturing zones in both the Baltics and Israel, designed to support civil and defense aviation needs, under the new venture.The companies also plan to develop a NATO-compliant logistics hub in Riga in cooperation with additional regional partners, as well as facilities dedicated to licensed aircraft Maintenance, Repair, and Overhaul (MRO) services, aircraft modernization, resale, and leasing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NUKK">Nukkleus</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:578/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_29_at_11_00_51_AM_png_e21f0150af.webp" alt="NUKK's Sentiment Meter and Message Volume as of 11:01 a.m. ET on Aug. 29, 2025 | Source: Stocktwits" width="578" height="61"><figcaption>NUKK's Sentiment Meter and Message Volume as of 11:01 a.m. ET on Aug. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that the stock is now tearing down walls set up by shorts.<stembedurl>https://stocktwits.com/Bfomo/message/627013481</stembedurl>Another user recommended buying and holding the shares.<stembedurl>https://stocktwits.com/Jumpinjackflash33/message/627013022</stembedurl>A five-member board of directors will lead the new venture along with an advisory board featuring aviation professionals, including two former Israeli Air Force pilots.The partnership will also aim to identify and finance early-stage technology companies in Israel that can be integrated into aviation and defense operations. The new venture will serve as the “cornerstone of Nukkleus’ European aviation and defense operations,” providing a strong foundation for future growth, the company said.The initiative comes at a time when ongoing geopolitical tensions continue to reshape regional defense priorities, the company noted, while adding that the global aircraft MRO market is projected to expand to $124 billion by 2034.NUKK stock is down by 86% this year, but has more than doubled in value over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-stock-gets-price-target-cut-from-stifel-as-it-gears-up-for-reverse-stock-split/chtTSAXRdNK">Lucid Stock Gets A Price Target Cut From Stifel As It Gears Up For A Reverse Stock Split: Retail Sees 50% Dive Post Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Nukkleus Stock Shot Up A Whopping 37% Today – Here’s What Happened

Nukkleus and Mandragola stated they intend to establish advanced manufacturing zones in both the Baltics and Israel, designed to support civil and defense aviation needs, under a new venture. 

Outlook Therapeutics, Inc. (OTLK) announced on Thursday that the U.S. Food and Drug Administration (FDA) has declined to approve its investigational drug Lytenava for the treatment of wet age-related macular degeneration. Shares of the company nosedived by over 66% in Thursday’s pre-market session following the announcement.The agency cited a lack of substantial evidence of effectiveness as the basis for its decision. Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older. Wet age-related macular degeneration (wet AMD) is an advanced form of AMD where abnormal, leaky blood vessels grow under the retina, leading to rapid vision loss.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> trended within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.The agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/28/3140631/0/en/Outlook-Therapeutics-Provides-Regulatory-Update-on-U-S-Food-and-Drug-Administration-Review-of-ONS-5010-LYTENAVA-bevacizumab-vikg-for-the-Treatment-of-Wet-AMD.html">noted</a> in its letter to the company that the drug did not meet the primary efficacy endpoint in a study and recommended that confirmatory evidence of efficacy be submitted to support the application.CEO Bob Jahr said that the company is very disappointed with this outcome and intends to meet with the agency to receive additional clarity on requirements for approval.“It is important to also note that the CRL (letter) identified no other outstanding deficiencies in our BLA (application),” Jahr added.The company also said that it intends to continue its efforts to expand Lytenava into additional markets in Europe. It has already been granted Marketing Authorization by the European Commission in the European Union and Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.OTLK is up by 26% this year but down by 68% over the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lisa-cook-to-sue-trump-administration-firing-her-federal-reserve-board/chsH6GARdjs">Lisa Cook To Sue Trump Administration For Firing Her From Federal Reserve Board: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Outlook Therapeutics Stock Nose-Dives 66% In Pre-Market – Here’s Why

The US FDA declined to approve the firm’s investigational drug Lytenava for the treatment of wet age-related macular degeneration, citing a lack of substantial evidence of effectiveness.

Medical device company enVVeno Medical Corporation (NVNO) on Wednesday announced that the U.S. Food &amp; Drug Administration (FDA) has refused to approve its application for its lead product, VenoValve, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).Following the announcement, NVNO shares plunged 71% by Wednesday afternoon, at the time of writing.Severe deep chronic venous insufficiency (CVI) is a long-term condition where the veins in the legs have difficulty returning blood to the heart, leading to blood pooling and various symptoms like swelling, aching, and skin changes. This occurs primarily due to damaged or weakened valves within the deep leg veins.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVNO">NVNO</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while retail chatter rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:563/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_12_41_02_PM_png_bca2208bb7.webp" alt="NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="61"><figcaption>NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the company renegotiating with the FDA.<stembedurl>https://stocktwits.com/Flying_Trader2/message/625960642</stembedurl>Another user said that they see no value in the company with the VenoValve rejection.<stembedurl>https://stocktwits.com/kmx_swing/message/625941525</stembedurl>The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://envveno.com/envveno-receives-not-approvable-letter-from-the-fda-for-the-venovalve/">said</a> in a letter that it completed its review of the company’s application for VenoValve but has decided that it is unable to approve it in its current form. The agency said that data generated by the company for the application was not sufficient on its own to determine the favorability of the benefit-risk profile for VenoValve.The FDA also raised concerns about bias and the possibility that clinical improvement occurred as a result of the patients being enrolled in a study. The agency further raised safety concerns, which were attributed to the VenoValve open surgical procedure, and which required re-hospitalizations.CEO Robert Berman said that the company is disappointed by the FDA’s decision and highlighted that a high percentage of patients in a study showed significant clinical improvement after receiving VenoValve. Berman added that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of the device.The firm’s next steps may include a meeting with the FDA to discuss requirements for a potential resubmission of the VenoValve or appeal of the decision, along with appropriate next steps.NVNO stock is down by 59% this year and by about 77% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-says-tesla-model-yl-might-not-ever-come-to-us-markets/chsitLlRdhq">Elon Musk Said Tesla’s Model Y L Might Not Ever Come To US Markets – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It?

enVVeno Medical Corporation CEO Robert Berman said that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of its VenoValve device. 

Broadband provider WideOpenWest, Inc. (WOW) shares soared in Tuesday’s premarket session after the company announced a going-private transaction.The Engelwood, Colorado-based company said it has reached a definitive agreement under which affiliated investment funds of DigitalBridge and Crestview Partners will acquire all of its outstanding shares not already owned by Crestview and its affiliates.The deal has been negotiated for $5.20 per share in cash, with an enterprise value of about $1.5 billion.The per-share transaction value represented a 54% premium over WideOpenWest’s closing price on Monday.&nbsp;The company noted that the purchase price represented a 37.2% premium to the $3.79 stock price, before the initial non-binding offer of $4.80 submitted by the purchaser group on May 2, 2024.Reacting to the proposed transaction,&nbsp;<a href="https://stocktwits.com/symbol/WOW">WideOpenWest stock</a> jumped 46.63% to $5.On Stocktwits, retail sentiment toward the stock turned to ‘extremely bullish’ (94/100) by early Tuesday, from ‘neutral’ a day ago. The message volume on the stream perked up to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/46;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_12_at_5_14_45_AM_png_3d57ce659d.webp" alt="Screenshot 2025-08-12 at 5.14.45 AM.png" width="623" height="46"><figcaption>WOW sentiment and message volume as of 5:15 a.m. ET, Aug. 12 | source: Stocktwits</figcaption></figure>CEO Teresa Elder said,&nbsp; "WOW!'s next chapter with DigitalBridge and Crestview will bring new and exciting opportunities to our stakeholders and enhance our position as a trusted provider of fast, reliable, and affordable broadband solutions."Jonathan Friesel, Senior Managing Director and Head of Fiber at DigitalBridge, said, “We intend to invest in expanding and upgrading WOW!'s networks, adopting new technologies, and ensuring the organization has the resources and support needed to continue delivering fast, reliable internet service and a high-quality customer experience at competitive prices."WideOpenWest’s board has unanimously approved the proposed transaction. Crestview, whose holding represented 37% of WideOpenWest's outstanding shares, has agreed to vote in favor of the transaction, subject to specific terms and conditions set forth therein.The transaction is expected to close by the end of the year or in the first quarter of 2026, subject to the satisfaction of the closing conditions, including the receipt of stockholder approval and of required regulatory approvals.&nbsp;Upon completion of the transaction, WideOpenWest will no longer be traded or listed on any public securities exchange.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/el-erian-says-us-china-tariff-truce-eliminates-risk-of-empty-shelves-for-christmas-but-won-t-solve-bigger-issues/chrDylBRd71"> El-Erian Says US-China Tariff Truce Eliminates Risk Of ‘Empty Shelves For Christmas’, But Won’t Solve Bigger Issues ‘Far Beyond Economics’</a>

WideOpenWest stock, WideOpenWest stock, WOW stock, WIOW stock price, why it’s moving, premarket jump

Why Shares Of Broadband Provider WideOpenWest Are Shooting Higher Premarket Today

The going-private deal has been negotiated for $5.20 per share in cash, with an enterprise value of about $1.5 billion.

BigBear.ai Holdings, Inc. (BBAI) shares tumbled in Monday’s extended trading after the artificial intelligence (AI)-powered decision intelligence solutions company announced an across-the-board miss for its second quarter.On Stocktwits, BigBear stock was the top-trending ticker by late Monday. The 24-hour message volume change on the stock’s stream leading up to late Monday was 1,872%.Retail sentiment toward the stock improved to ‘bullish’ (69/100) by late Monday from ‘neutral’ a day ago.<figure class="image"><img style="aspect-ratio:620/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_11_12_50_PM_png_d22c0e8760.webp" alt="Screenshot 2025-08-11 at 11.12.50 PM.png" width="620" height="63"><figcaption>BBAI sentiment and message volume as of 11:10 p.m. ET, Aug. 11 | source: Stocktwits</figcaption></figure>The McLean, Virginia-based company reported a loss of $0.71 per share for the second quarter of the fiscal year 2025, significantly wider than the year-ago loss of $0.06 per share. The Fiscal.ai-compiled called for a loss of $0.06 per share.Non-cash changes in derivative liabilities ($135.8 million) related to the changes in the fair value of the convertible features of the 2029 notes and warrants, and a non-cash goodwill impairment charge ($70.6 million) primarily weighed down on the bottom-line result.Quarterly revenue fell to $32.47 million from $39.78 million, missing the consensus of $40.58 million. The company attributed the lower revenue primarily to lower volume on certain army programs.The gross margin also contracted to 25% from 27.8%.&nbsp;CEO Kevin McAleenan said, “Our capital raising activities this quarter coincide with the tremendous opportunities we see coming from the One Big Beautiful Bill, particularly in the Department of Homeland Security, and several of which are uniquely aligned to our core capabilities.”BigBear guided 2025 revenue in the range of $125 million to $140 million, below the $167.74-million consensus estimate. The company withdrew its previously issued adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) guidance for the year, citing the uncertainty on certain Army programs as well as new anticipated growth investment spending in the second half of the year.Retailer users of the Stocktwits platform weren’t ready to give up yet on the stock. “Best time to buy is now,” said a bullish watcher.<stembedurl>https://stocktwits.com/astrix79/message/624708218</stembedurl>Another user expected a climb back soon after the steep drop.<stembedurl>https://stocktwits.com/astrix79/message/624707776</stembedurl>In overnight trading, BigBear stock was down over 30% at $4.90. If the losses are sustained in Tuesday’s regular session, the stock is on track to experience its worst day in more than a year, according to Koyfin data.The stock has gained approximately 60% for the year, excluding the after-hours decline.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/us-stock-futures-jittery-despite-us-chins-trade-truce-extension/chrDoS4Rder">US Stock Futures Jittery Despite US-China Trade Truce Extension: Strategist Says Tamer Inflation Print Key For Constructive Longer-Term Outlook</a>

BigBear Retail Traders Say ‘Time To Buy’ After Stock Craters Over 30% On Q2 Miss Amid Army Contract Scaleback

Quarterly revenue fell to $32.47 million from $39.78 million, missing the consensus of $40.58 million. 

Mullen Automotive, Inc. (MULN) announced on Thursday that its previously announced name change will take effect on July 28.The company will change its <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.mullenusa.com/mullen-announces-company-name-change-to-bollinger-innovations-inc-effective-july-28-2025">name</a> to Bollinger Innovations, Inc. Its common stock will begin trading on The Nasdaq Capital Market under the new stock symbol BINI at market open on July 28.Mullen CEO David Michery said that the name change is aimed at bringing the company’s products and brands together under one unified identity. Bollinger is the name of Mullen’s majority-owned EV truck company.The name and stock symbol change does not affect the company’s legal structure or business operations, it said, adding that stockholders need not take any action regarding the changes.MULN stock is trading 14% lower at the time of writing on Thursday afternoon.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MULN">Mullen</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours while message volume stayed at ‘high’ levels. According to Stocktwits data, retail chatter around Mullen has increased 35% over the past 24 hours.<figure class="image"><img style="aspect-ratio:1336/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_24_at_1_15_36_PM_png_be73fc102e.webp" alt="MULN's Sentiment Meter and Message Volume as of 1:15 p.m. ET on July 24, 2025 | Source: Stocktwits" width="1336" height="122"><figcaption>MULN's Sentiment Meter and Message Volume as of 1:15 p.m. ET on July 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company might have a plan behind the name change.<stembedurl>https://stocktwits.com/ItsMeToo/message/622296000</stembedurl>Southern California-based Mullen builds commercial electric vehicles. Its commercial EV lineup includes the Mullen ONE, a cargo van, and the Mullen THREE, a cab chassis truck. It's majority-owned EV truck company, Bollinger Motors, makes the Bollinger B4 electric truck.In June, the company announced that it had raised its stake in Bollinger Motors by acquiring an additional 21% of the company, thereby increasing its total ownership to 95%. This acquisition followed the company's resolution of claims and debt that had led to a court-ordered receivership for Bollinger.MULN stock has wiped nearly all of its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/novavax-announces-positive-preclinical-data-from-bird-flu-vaccine/ch8zRUiR5Ht">Novavax Announces Positive Preclinical Data From Bird Flu Vaccine: Retail Wonders When Will The Stock Be Fairly Valued</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Mullen Automotive logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Mullen Automotive Name Change To Be Effective July 28, But Retail’s Not Optimistic Yet

Mullen Automotive will change its name to Bollinger Innovations, Inc. 

BlackRock Institutional Trust Company N.A. - iShares Micro-Cap ETF

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWC News

IWC iShares Micro-Cap ETF